Feedback / Questions
visugromab (CTL-002) - CatalYm
https://www.businesswire.com/news/home/20250930495985/en/CatalYm-Announces-First-Patient-Dosed-in-Phase-2b-Trial-Evaluating-Visugromab-in-Combination-with-Chemoimmunotherapy-as-First-Line-Treatment-in-Metastatic-Non-squamous-NSCLC?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA%3D%3D
Sep 30, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next